Edgewise Therapeutics, Inc.
EWTX
$29.69
-$0.81-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.48% | -12.60% | 11.48% | -2.86% | -16.21% |
| Total Depreciation and Amortization | 0.88% | 0.53% | 2.35% | -11.92% | 4.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.19% | 9.02% | -22.51% | 38.97% | 41.07% |
| Change in Net Operating Assets | 474.75% | 72.35% | 46.11% | -168.55% | 176.20% |
| Cash from Operations | -10.97% | -6.73% | 13.95% | -40.47% | 1.52% |
| Capital Expenditure | 17.98% | -78.00% | -13.64% | 83.94% | 47.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 39.18% | 122.09% | -468.93% | 107.31% | -18.11% |
| Cash from Investing | 39.33% | 122.02% | -469.42% | 109.82% | -17.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 139.60% | -99.12% | 8,223.44% | -21.90% | -18.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 200.00% | -- | 100.00% |
| Cash from Financing | 139.60% | -99.12% | 8,367.43% | -23.21% | -13.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 482.72% | 139.88% | -178.95% | 362.90% | -337.70% |